Insight Molecular Diagnostics (IMDX) is a precision diagnostics company with disruptive transplant technology and strong recent price momentum. IMDX has surged 158% over the past year and is trading at...
Insight Molecular Diagnostics: Q3 Earnings Snapshot
On track to submit GraftAssureDx™ for FDA review by year-end On track for commitment to have 20 transplant centers globally engaged with GraftAssure technology by end of 2025 GraftAssure assay’s...
NASHVILLE, Tenn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will report third quarter 2025 financial results after the market...
Steven Tahmooressi to lead global marketing efforts for GraftAssure family of assays and future products Brings 25 years of experience driving new product adoption across geographies in transplantation,...
In a report released today, Thomas Flaten from Lake Street maintained a Buy rating on Insight Molecular Diagnostics, with a price target of $8.00. The company’s shares closed last Friday at $3.35.Elevate...
American Journal of Transplantation study positions GraftAssure as potentially essential in managing immunosuppression treatment in kidney transplant patients with certain cancers GraftAssure used to...
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Insight Molecular...
IMDX to host symposium on Wednesday, September 24 th to discuss GraftAssureIQ™ at International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) annual meeting Presenting...
5,000-participant, multi-center registry supported by iMDx’s central lab and transplant center partners New hospital-based data seeks to further differentiate pending kitted assay that measures biomarker...